### Indication
Psoriasis of unspecified type  
**ICD11 code:** EA90.Z

### INN
Betamethasone

### Medicine type
Chemical agent

### List type
Core

### Formulations
- Local > Topical > Cream: 0.1% (as valerate)
- Local > Topical > Ointment: 0.1% (as valerate)

### EML status history
- First added in 1977 ([TRS 615](#))
- Changed in 1979 ([TRS 641](#))
- Changed in 2007 ([TRS 950](#))
- Changed in 2021

### Sex
All

### Age
Also recommended for children

### Age restriction
Hydrocortisone preferred in neonates.

### Therapeutic alternatives
Medicines within the same pharmacological class can be used

### Therapeutic alternatives limitations
- Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup:D07AC Corticosteroids, potent (group III).

### Therapeutic alternatives limitations for EMLc
- Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup:D07AC Corticosteroids, potent (group III).

### Patent information
- Patents have expired in most jurisdictions
- Read more about patents.

### Wikipedia
- Betamethasone

### DrugBank
- Betamethasone

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, D07AC Corticosteroids, potent (group III), be specified as therapeutic alternatives under the square box listing for betamethasone on the EML and EMLc.